Literature DB >> 32411809

Early Experience With Eravacycline for Complicated Infections.

Sara Alosaimy1, Kyle C Molina2, Kimberly C Claeys3, Justin Andrade4, James Truong4, Madeline A King5,6, Benjamin M Pullinger5,6, Glen Huang7, Taylor Morrisette1, Abdalhamid M Lagnf1, Susan L Davis1,8, Michael J Rybak1,9,10.   

Abstract

Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen was Klebsiella pneumoniae, and 30-day survival was 74%. Absence of 30-day recurrence and resolution of signs and symptoms of infection were 91% and 57%, respectively. ERV was well-tolerated, with adverse events leading to drug discontinuation in one patient. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.

Entities:  

Keywords:  eravacycline; multidrug-resistant Enterobacteriaceae; tetracyclines

Year:  2020        PMID： 32411809      PMCID： PMC7210802          DOI： 10.1093/ofid/ofaa071

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN： 2328-8957            Impact factor:   3.835


  8 in total

1.  The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

Authors:  Timothy Babinchak; Evelyn Ellis-Grosse; Nathalie Dartois; Gilbert M Rose; Evan Loh
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

2.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

3.  Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.

Authors:  Joseph Solomkin; David Evans; Algirdas Slepavicius; Patrick Lee; Andrew Marsh; Larry Tsai; Joyce A Sutcliffe; Patrick Horn
Journal:  JAMA Surg       Date:  2017-03-01       Impact factor: 14.766

Review 4.  Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.

Authors:  George G Zhanel; Doris Cheung; Heather Adam; Sheryl Zelenitsky; Alyssa Golden; Frank Schweizer; Bala Gorityala; Philippe R S Lagacé-Wiens; Andrew Walkty; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

5.  Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia.

Authors:  Yardena Siegman-Igra; Boaz Fourer; Ruth Orni-Wasserlauf; Yoav Golan; Aliza Noy; David Schwartz; Michael Giladi
Journal:  Clin Infect Dis       Date:  2002-04-30       Impact factor: 9.079

Review 6.  Evaluation of Eravacycline: A Novel Fluorocycline.

Authors:  Sara Alosaimy; Jacinda C Abdul-Mutakabbir; Razie Kebriaei; Sarah C J Jorgensen; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2020-02-21       Impact factor: 4.705

Review 7.  The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis.

Authors:  Jian Wang; Yaping Pan; Jilu Shen; Yuanhong Xu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-04-05       Impact factor: 3.944

8.  IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.

Authors:  Joseph S Solomkin; Janis Gardovskis; Kenneth Lawrence; Philippe Montravers; Angie Sway; David Evans; Larry Tsai
Journal:  Clin Infect Dis       Date:  2019-08-30       Impact factor: 9.079
  8 in total
  4 in total

Review 1.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

2.  Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials.

Authors:  Tomefa E Asempa; Sergey Izmailyan; Kenneth Lawrence; David P Nicolau
Journal:  Open Forum Infect Dis       Date:  2020-11-13       Impact factor: 3.835

Review 3.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

4.  Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections.

Authors:  Taylor Morrisette; Sara Alosaimy; Julie V Philley; Carly Wadle; Catessa Howard; Andrew J Webb; Michael P Veve; Melissa L Barger; Jeannette Bouchard; Tristan W Gore; Abdalhamid M Lagnf; Iman Ansari; Carlos Mejia-Chew; Keira A Cohen; Michael J Rybak
Journal:  Open Forum Infect Dis       Date:  2021-01-07       Impact factor: 3.835
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.